Quintrio
Home

PHARMACEUTICAL PREPARATIONS

HCW Biologics Inc. Common Stock

HCWB

HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $0.77 – $0.865
Volume 11,763
Market cap $2M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.79M
Price / earnings
—
Price / book
0.24×
Price / sales
0.27×
EV / sales
1.13×
EV / EBITDA
-1.08×

Profitability

Earnings per share
-$9.57
Return on assets
-79.98%
Return on equity
-288.25%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.88×
Current ratio
0.06×
Quick ratio
0.06×
Cash ratio
0.04×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.14M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HCWB, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$135.57K$6.54M$27.01K$15.61K$6.55K$5.07K$394.8K$426.42K
Cost of revenue$229.46K$11.07K$21.61K$12.49K$5.24K$4.05K$315.84K$341.14K
Gross profit-$93.89K$6.53M$5.4K$3.12K$1.31K$1.01K$78.96K$85.29K
Selling, general and administrative$1.87M$1.83M$3.1M$1.89M$2.1M$2.23M-$13.73M$2.58M
Research and development$1.2M$1.26M$1.33M$1.4M$1.23M$1.48M$1.05M$1.19M
Total operating expenses$3.07M$3.3M$4.47M$3.3M$3.47M$1.97M$3.23M$3.77M
Operating income-$3.17M$3.24M-$4.46M-$3.29M-$3.46M-$1.97M-$3.15M-$3.68M
Interest expense-$100.54K-$109.27K-$212.13K-$127.07K-$228.71K-$255.82K-$260.38K-$229.06K
Income before taxes-$5.22M$3.8M$719.23K-$4.55M-$1.93M-$2.2M-$3.37M-$3.9M
Income taxes$0$330.19K$0$0$0$0$0$0
Net income-$5.22M$3.47M$719.23K-$4.55M-$1.93M-$2.2M-$3.37M-$3.9M
Net income attributable to common shareholders-$15.37M$1.98M-$3.47M-$4.55M-$12.08M-$2.2M-$3.37M-$3.9M
EBITDA-$3.04M$3.38M-$4.28M-$3.12M-$3.17M-$1.55M$13.45M-$3.56M
Basic earnings per share-$11.58$2.22-$6.43-$12.12-$40.72-$11.82-$6.98-$24.78
Diluted earnings per share-$11.58$2.22-$6.43-$12.12-$40.72-$11.82-$6.98-$24.78

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer

HCW Biologics announced that its HCW11-040, a first-in-class tetravalent pembrolizumab-based immune checkpoint inhibitor, was selected as one of the top 150 abstracts out of 1,200 submissions for the Society for Immunotherapy of Cancer's 41st Annual Meeting. The candidate demonstrated superior performance compared to pembrolizumab in rejuvenating exhausted T cells and converting cold tumors to hot tumors in preclinical studies. The company also secured up to $10 million in debt financing.

GlobeNewswire Inc.

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

HCW Biologics Inc. announced an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a multi-cytokine fusion molecule designed to improve CAR-T cell manufacturing. The reagent demonstrated superior performance in preclinical studies, generating more potent and longer-lasting CAR-T cells while potentially reducing production costs compared to conventional methods.

GlobeNewswire Inc.

HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

HCW Biologics announced that its TGF-β trap and IL-15 fusion moiety promotes expansion of CD8+ T cells and NK cells, demonstrating clinical benefit in cancer patients and activity against HIV-1 and bronchopulmonary dysplasia. The company has incorporated this discovery into second-generation T Cell Engager (HCW11-018b) and Immune Checkpoint Inhibitor (HCW11-040) programs, with both candidates at IND-enabling stage and clinical studies planned for 2027.

GlobeNewswire Inc.

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

HCW Biologics Inc. (NASDAQ: HCWB) announced a 1-for-6 reverse stock split effective June 30, 2026, to ensure compliance with Nasdaq's minimum bid price rule following a Hearings Panel decision. The company successfully maintained stock prices above $1.00 per share for the required 20 trading days and will reduce outstanding shares from approximately 9.6 million to 1.6 million.

GlobeNewswire Inc.

HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules

HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, announced the pricing of a $1.5 million follow-on offering of 2,477,292 units at $0.6055 per unit. The company plans to use net proceeds for preclinical and clinical development of HCW9302 and general corporate purposes. Additionally, HCW Biologics negotiated to reduce the exercise price of existing warrants from $2.41 to $0.6055 per share, subject to shareholder approval.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jun 30, 20261-for-6reverse split
Apr 11, 20251-for-40reverse split